Home › Non-Small Cell Lung Cancer › NCT06626243
Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers
An International Multicenter Retrospective Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of clinical or pathological stage IIB (T1-2, hilar N1, M0) and III (any T, N1-2, M0) NSCLC surgically treated with robotic, VATS and open approach with radical intent from 1st of January 2016 to 31st of March 2024 * Received neoadjuvant chemo-immunotherapy or immunotherapy alone * Age \>= 18 years old at the moment of surgery Exclusion Criteria: * Age \<18 years old at the moment of surgery
About the study
The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced and resectable NSCLC who underwent lung resection by robotic, VATS and open approach after receiving neoadjuvant chemo-immunotherapy.
There are no risks for the patients, as this is a retrospective data collection.
Sponsor: Scientific Institute San Raffaele · Participants: 140 · Started: Sep 30, 2024
Contact the study team
- Pierluigi Novellis, Medical Doctor · Phone: 0226437202
Official record on ClinicalTrials.gov — NCT06626243
Locations in the U.S.
| Florida | Baptist Health South Florida, Miami |
| New York | Memorial Sloan Kettering Cancer Center, New York |
| West Virginia | West Virginia University, Morgantown |
Conditions
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.